167 related articles for article (PubMed ID: 30946242)
1. Cost-effectiveness of Pancreatic Cancer Surveillance in High-Risk Individuals: An Economic Analysis.
Corral JE; Das A; Bruno MJ; Wallace MB
Pancreas; 2019 Apr; 48(4):526-536. PubMed ID: 30946242
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Abdominal Ultrasound Versus Magnetic Resonance Imaging for Pancreatic Cancer Screening in Familial High-Risk Individuals in Japan.
Kowada A
Pancreas; 2020 Sep; 49(8):1052-1056. PubMed ID: 32769852
[TBL] [Abstract][Full Text] [Related]
3. Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma.
Kumar S; Saumoy M; Oh A; Schneider Y; Brand RE; Chak A; Ginsberg GG; Kochman ML; Canto MI; Goggins MG; Hur C; Kastrinos F; Katona BW; Rustgi AK
Pancreas; 2021 Jul; 50(6):807-814. PubMed ID: 34149034
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds.
Rulyak SJ; Kimmey MB; Veenstra DL; Brentnall TA
Gastrointest Endosc; 2003 Jan; 57(1):23-9. PubMed ID: 12518126
[TBL] [Abstract][Full Text] [Related]
5. Endoscopic Ultrasound-Based Pancreatic Cancer Screening of High-Risk Individuals: A Prospective Observational Trial.
Gangi A; Malafa M; Klapman J
Pancreas; 2018; 47(5):586-591. PubMed ID: 29683970
[TBL] [Abstract][Full Text] [Related]
6. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals.
Harinck F; Konings IC; Kluijt I; Poley JW; van Hooft JE; van Dullemen HM; Nio CY; Krak NC; Hermans JJ; Aalfs CM; Wagner A; Sijmons RH; Biermann K; van Eijck CH; Gouma DJ; Dijkgraaf MG; Fockens P; Bruno MJ;
Gut; 2016 Sep; 65(9):1505-13. PubMed ID: 25986944
[TBL] [Abstract][Full Text] [Related]
7. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.
Joergensen MT; Gerdes AM; Sorensen J; Schaffalitzky de Muckadell O; Mortensen MB
Pancreatology; 2016; 16(4):584-92. PubMed ID: 27090585
[TBL] [Abstract][Full Text] [Related]
8. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry.
Paiella S; Capurso G; Cavestro GM; Butturini G; Pezzilli R; Salvia R; Signoretti M; Crippa S; Carrara S; Frigerio I; Bassi C; Falconi M; Iannicelli E; Giardino A; Mannucci A; Laghi A; Laghi L; Frulloni L; Zerbi A
Am J Gastroenterol; 2019 Apr; 114(4):665-670. PubMed ID: 30538291
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging or Endoscopic Ultrasonography for Detection and Surveillance of Pancreatic Neuroendocrine Neoplasms in Patients with Multiple Endocrine Neoplasia Type 1?
Daskalakis K; Tsoli M; Alexandraki KI; Angelousi A; Chatzellis E; Tsolakis AV; Karoumpalis I; Kolomodi D; Kassi E; Kaltsas G
Horm Metab Res; 2019 Sep; 51(9):580-585. PubMed ID: 31295747
[TBL] [Abstract][Full Text] [Related]
11. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance.
Kluijt I; Cats A; Fockens P; Nio Y; Gouma DJ; Bruno MJ
J Clin Gastroenterol; 2009 Oct; 43(9):853-7. PubMed ID: 19417680
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of high-risk individuals for pancreatic cancer with EUS and MRI: A meta-analysis.
Kogekar N; Diaz KE; Weinberg AD; Lucas AL
Pancreatology; 2020 Dec; 20(8):1739-1746. PubMed ID: 33077384
[TBL] [Abstract][Full Text] [Related]
13. Screening for pancreatic cancer in familial high-risk individuals: A systematic review.
Lu C; Xu CF; Wan XY; Zhu HT; Yu CH; Li YM
World J Gastroenterol; 2015 Jul; 21(28):8678-86. PubMed ID: 26229410
[TBL] [Abstract][Full Text] [Related]
14. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.
Langer P; Kann PH; Fendrich V; Habbe N; Schneider M; Sina M; Slater EP; Heverhagen JT; Gress TM; Rothmund M; Bartsch DK
Gut; 2009 Oct; 58(10):1410-8. PubMed ID: 19470496
[TBL] [Abstract][Full Text] [Related]
15. Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study.
Shin EJ; Topazian M; Goggins MG; Syngal S; Saltzman JR; Lee JH; Farrell JJ; Canto MI
Gastrointest Endosc; 2015 Nov; 82(5):812-8. PubMed ID: 25930097
[TBL] [Abstract][Full Text] [Related]
16. Is early diagnosis of pancreatic cancer fiction? Surveillance of individuals at high risk for pancreatic cancer.
Harinck F; Poley JW; Kluijt I; Fockens P; Bruno MJ;
Dig Dis; 2010; 28(4-5):670-8. PubMed ID: 21088419
[TBL] [Abstract][Full Text] [Related]
17. A clinical and economic evaluation of endoscopic ultrasound for patients at risk for familial pancreatic adenocarcinoma.
Rubenstein JH; Scheiman JM; Anderson MA
Pancreatology; 2007; 7(5-6):514-25. PubMed ID: 17912015
[TBL] [Abstract][Full Text] [Related]
18. Early diagnosis of pancreatic cancer, time to screen high-risk individuals?
Iglesias-Garcia J; Lariño-Noia J; Dominguez-Muñoz JE
Minerva Gastroenterol Dietol; 2011 Jun; 57(2):205-12. PubMed ID: 21587149
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Yield From Screening Asymptomatic Individuals at High Risk for Pancreatic Cancer: A Meta-analysis of Cohort Studies.
Corral JE; Mareth KF; Riegert-Johnson DL; Das A; Wallace MB
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):41-53. PubMed ID: 29775792
[TBL] [Abstract][Full Text] [Related]
20. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature.
Ghatnekar O; Andersson R; Svensson M; Persson U; Ringdahl U; Zeilon P; Borrebaeck CA
Int J Cancer; 2013 Nov; 133(10):2392-7. PubMed ID: 23649606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
